

(19) **DANMARK**

(10) **DK/EP 2686047 T3**



(12)

Oversættelse af europæisk patentskrift

Patent- og
Varemærkestyrelsen

-
- (51) Int.Cl.: **A 61 M 5/315 (2006.01)** **A 61 M 5/00 (2006.01)** **A 61 M 5/145 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2021-08-23**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2021-06-02**
- (86) Europæisk ansøgning nr.: **12710205.1**
- (86) Europæisk indleveringsdag: **2012-03-15**
- (87) Den europæiske ansøgnings publiceringsdag: **2014-01-22**
- (86) International ansøgning nr.: **EP2012054560**
- (87) Internationalt publikationsnr.: **WO2012123543**
- (30) Prioritet: **2011-03-16 EP 11158491**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **Sanofi-Aventis Deutschland GmbH, Brüningstraße 50, 65929 Frankfurt am Main, Tyskland**
- (72) Opfinder: **JUGL, Michael, c/o SANOFI-AVENTIS DEUTSCHLAND GmbH, 65926 Frankfurt am Main, Tyskland**
KRAFT, Torsten, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Tyskland
- (74) Fuldmægtig i Danmark: **RWS Group, Europa House, Chiltern Park, Chiltern Hill, Chalfont St Peter, Bucks SL9 9FG, Storbritannien**
- (54) Benævnelse: **DRIVMEKANISME TIL MEDICINAFGIVELSESANORDNING SAMT MEDICINAFGIVELSESANORDNING**
- (56) Fremdragne publikationer:
WO-A1-01/72360
WO-A1-01/78812
WO-A1-02/076535
WO-A1-02/076538
US-A- 5 261 882

DESCRIPTION

[0001] The present invention relates to a drive mechanism for a drug delivery device and to a drug delivery device that is provided with such a drive mechanism.

[0002] EP 1 372 768 B1 describes a drive mechanism for an injection device in which a semi-rigid belt with a track is used to drive a piston member. A belt drive means is provided to drive the belt a preselected way. It comprises a tooth for a selective engagement with the track and allows an advancement of the belt only in one direction.

[0003] WO 01/78812 A1 describes a drug delivery device comprising a piston rod and rotating means in engagement with the piston rod. The rotating means is provided with a mechanism comprising a helical spring wound tightly around an axle, one end of the spring being fixed to the housing and the other end being in a free state.

[0004] WO 02/076538 A1 describes an injection device with a drive mechanism comprising a piston member, a semi-rigid belt connected at a first end to the piston member, a belt drive means to drive the semi-rigid belt and a dose setting mechanism. The belt drive means comprises a first cable means connected at a first end to a second end of the semi-rigid belt and at a second end to a first spool.

[0005] WO 02/076535 A1 describes an injection device with a drive mechanism comprising a piston member, a semi-rigid belt connected to the piston member, a belt drive means and a dose setting mechanism. The semi-rigid belt includes a track incorporated therein, and the belt drive means comprises a tooth for selective engagement with the track to drive the belt.

[0006] WO 01/72360 A1 describes a flexible piston rod for an injection device in the form of a helical spring made up from a number of narrowly adjacent turns of windings providing an external thread fitting into the internal thread of a nut element.

[0007] US 5 261 882 A describes a spring-powered syringe comprising a non-circular, nonlinear configuration of a negator spring. A piston head is driven by a row of linked spheres, and a drive means is permanently connected.

[0008] It is an object of the present invention to provide a new drive mechanism and a drug delivery device of compact dimensions.

[0009] This object is achieved with a drive mechanism according to claim 1 and a drug delivery device according to claim 10, respectively. Further objects are achieved with embodiments according to the dependent claims.

[0010] The term "drug", as used herein, preferably means a pharmaceutical formulation containing at least one pharmaceutically active compound,

wherein in one embodiment the pharmaceutically active compound has a molecular weight up to 1500 Da and/or is a peptide, a protein, a polysaccharide, a vaccine, a DNA, a RNA, an enzyme, an antibody, a hormone or an oligonucleotide, or a mixture of the above-mentioned pharmaceutically active compound,

wherein in a further embodiment the pharmaceutically active compound is useful for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism, acute coronary syndrome (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and/or rheumatoid arthritis,

wherein in a further embodiment the pharmaceutically active compound comprises at least one peptide for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy,

wherein in a further embodiment the pharmaceutically active compound comprises at least one human insulin or a human insulin analogue or derivative, glucagon-like peptide (GLP-1) or an analogue or derivative thereof, or exedin-3 or exedin-4 or an analogue or derivative of exedin-3 or exedin-4.

[0011] Insulin analogues are for example Gly(A21), Arg(B31), Arg(B32) human insulin; Lys(B3), Glu(B29) human insulin; Lys(B28), Pro(B29) human insulin; Asp(B28) human insulin; human insulin, wherein proline in position B28 is replaced by Asp, Lys, Leu, Val or Ala and wherein in position B29 Lys may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.

[0012] Insulin derivatives are for example B29-N-myristoyl-des(B30) human insulin; B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl LysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N-palmitoyl-ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-Y-glutamyl)-des(B30) human insulin; B29-N-(N-lithocholyl-Y-glutamyl)-des(B30) human insulin; B29-N-(ω -carboxyheptadecanoyl)-des(B30) human insulin and B29-N-(ω -carboxyheptadecanoyl) human insulin.

[0013] Exendin-4 for example means Exendin-4(1-39), a peptide of the sequence H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂.

[0014] Exendin-4 derivatives are for example selected from the following list of compounds:

H-(Lys)4-des Pro36, des Pro37 Exendin-4(1-39)-NH₂,

H-(Lys)5-des Pro36, des Pro37 Exendin-4(1-39)-NH₂,

des Pro36 [Asp28] Exendin-4(1-39),

des Pro36 [IsoAsp28] Exendin-4(1-39),

des Pro36 [Met(O)14, Asp28] Exendin-4(1-39),
 des Pro36 [Met(O)14, IsoAsp28] Exendin-4(1-39),
 des Pro36 [Trp(O2)25, Asp28] Exendin-4(1-39),
 des Pro36 [Trp(O2)25, IsoAsp28] Exendin-4(1-39),
 des Pro36 [Met(O)14 Trp(O2)25, Asp28] Exendin-4(1-39),
 des Pro36 [Met(O)14 Trp(O2)25, IsoAsp28] Exendin-4(1-39); or
 des Pro36 [Asp28] Exendin-4(1-39),
 des Pro36 [IsoAsp28] Exendin-4(1-39),
 des Pro36 [Met(O)14, Asp28] Exendin-4(1-39),
 des Pro36 [Met(O)14, IsoAsp28] Exendin-4(1-39),
 des Pro36 [Trp(O2)25, Asp28] Exendin-4(1-39),
 des Pro36 [Trp(O2)25, IsoAsp28] Exendin-4(1-39),
 des Pro36 [Met(O)14 Trp(O2)25, Asp28] Exendin-4(1-39),
 des Pro36 [Met(O)14 Trp(O2)25, IsoAsp28] Exendin-4(1-39),

wherein the group -Lys6-NH₂ may be bound to the C-terminus of the Exendin-4 derivative;

or an Exendin-4 derivative of the sequence

H-(Lys)6-des Pro36 [Asp28] Exendin-4(1-39)-Lys6-NH₂,
 des Asp28 Pro36, Pro37, Pro38Exendin-4(1-39)-NH₂,
 H-(Lys)6-des Pro36, Pro38 [Asp28] Exendin-4(1-39)-NH₂,
 H-Asn-(Glu)5des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-NH₂,
 des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-(Lys)6-NH₂,
 H-(Lys)6-des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-(Lys)6-NH₂,
 H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-(Lys)6-NH₂,
 H-(Lys)6-des Pro36 [Trp(O2)25, Asp28] Exendin-4(1-39)-Lys6-NH₂,
 H-des Asp28 Pro36, Pro37, Pro38 [Trp(O2)25] Exendin-4(1-39)-NH₂,
 H-(Lys)6-des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28] Exendin-4(1-39)-NH₂,
 H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28] Exendin-4(1-39)-NH₂,

des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
H-(Lys)6-des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
H-(Lys)6-des Pro36 [Met(O)14, Asp28] Exendin-4(1-39)-Lys6-NH2,
des Met(O)14 Asp28 Pro36, Pro37, Pro38 Exendin-4(1-39)-NH2,
H-(Lys)6-des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-NH2,
H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-NH2,
des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
H-(Lys)6-des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
H-Asn-(Glu)5 des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
H-Lys6-des Pro36 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(1-39)-Lys6-NH2,
H-des Asp28 Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25] Exendin-4(1-39)-NH2,
H-(Lys)6-des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-NH2,
H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(1-39)-NH2,
des Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
H-(Lys)6-des Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(S1-39)-(Lys)6-NH2,
H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2;
or a pharmaceutically acceptable salt or solvate of any one of the afore-mentioned Exedin-4 derivative.

[0015] Hormones are for example hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists as listed in Rote Liste, ed. 2008, Chapter 50, such as Gonadotropine (Follitropin, Lutropin, Choriongonadotropin, Menotropin), Somatropine (Somatropin), Desmopressin, Terlipressin, Gonadorelin, Triptorelin, Leuprorelin, Buserelin, Nafarelin, Goserelin.

[0016] A polysaccharide is for example a glucosaminoglycane, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra low molecular weight heparin or a derivative thereof, or a sulphated, e.g. a poly-sulphated form of the above-mentioned polysaccharides, and/or a pharmaceutically acceptable salt thereof. An example of a pharmaceutically acceptable salt of

a poly-sulphated low molecular weight heparin is enoxaparin sodium.

[0017] Pharmaceutically acceptable salts are for example acid addition salts and basic salts. Acid addition salts are e.g. HCl or HBr salts. Basic salts are e.g. salts having a cation selected from alkali or alkaline, e.g. Na⁺, or K⁺, or Ca²⁺, or an ammonium ion N⁺(R1)(R2)(R3)(R4), wherein R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1-C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10-heteroaryl group. Further examples of pharmaceutically acceptable salts are described in "Remington's Pharmaceutical Sciences" 17. ed. Alfonso R. Gennaro (Ed.), Mark Publishing Company, Easton, Pa., U.S.A., 1985 and in Encyclopedia of Pharmaceutical Technology.

[0018] Pharmaceutically acceptable solvates are for example hydrates.

[0019] The housing of the drug delivery device can be an exterior housing or some kind of an insert connected with an exterior housing. The housing may enable the safe, correct, and/or easy handling of the device and/or may be provided to protect the device from harmful liquids, dust or dirt. The housing can be unitary or a multipart component and may house a cartridge, from which doses of a drug can be dispensed. The housing may be provided with a lid, so that it can be opened to insert a cartridge containing a drug. The drive mechanism can be used to expel a drug from a cartridge that is inserted in the housing. The drug delivery device can be a disposable or re-usable device. The drug may be administered by a needle, or the device may be needle-free.

[0020] The drive mechanism comprises a flexible advance cable bearing a coupling feature of longitudinal extension. The advance cable is guided by a guide means. A drive means engages the coupling feature and thus enables an advancement of the advance cable according to the guide means. An end piece is provided to push a plug or bung of a cartridge containing a drug, and the end piece is driven by the advance cable. The drive means is provided for a permanent engagement with the coupling feature. This allows a permanent advancement of the plug or bung by means of the drive mechanism.

[0021] The advance cable is provided with beads or balls having an outer diameter that exceeds the outer diameter of the advance cable and corresponds to the inner diameter of the cartridge.

[0022] In a further embodiment of the drive mechanism, the advance cable is a plastics material, and the beads or balls are formed as integral parts of the advance cable.

[0023] In a further embodiment of the drive mechanism, the beads or balls are separate parts arranged according to the guide means, and the advance cable passes through the beads or balls.

[0024] In a further embodiment of the drive mechanism, the drive means is a worm or pinion,

and the coupling feature is a screw thread.

[0025] In a further embodiment of the drive mechanism, the drive means is a worm or pinion, and the coupling feature is a sequence of annular protrusions.

[0026] In a further embodiment of the drive mechanism, the drive means is a worm or pinion, and the coupling feature is a rack.

[0027] In a further embodiment of the drive mechanism, the advance cable is a plastics material, and the end piece is formed as an integral part of the advance cable.

[0028] In a further embodiment of the drive mechanism, the end piece is applied to the advance cable as a separate part formed from a metal.

[0029] In a further embodiment of the drive mechanism, a piston rod is driven by the advance cable, and the end piece is provided on the piston rod.

[0030] In a further embodiment of the drive mechanism, the piston rod is driven parallel to the advance cable.

[0031] The drive mechanism is particularly suitable for a permanent delivery of a drug from a compact drug delivery device, which may be carried on the body.

[0032] The drug delivery device comprises a housing and a flexible advance cable bearing a coupling feature of longitudinal extension, which is arranged inside the housing. A guide means, which guides the advance cable, is formed inside the housing. A drive means engages the coupling feature and thus enables an advancement of the advance cable according to the guide means. An end piece is provided to push a plug or bung of a cartridge containing a drug and is driven by the advance cable. The drive means is provided for a permanent engagement with the coupling feature.

[0033] In an embodiment of the drug delivery device, the end piece is applied to the advance cable.

[0034] In a further embodiment of the drug delivery device, the end piece is located on a piston rod, and the piston rod is advanced by the advance cable.

[0035] The length of the advance cable may exceed the dimensions of the housing, and the advance cable may be bent to fit into the housing. This allows particularly compact dimensions of the drug delivery device.

[0036] In the following, examples and embodiments of the drive mechanism and the drug delivery device are described in detail in conjunction with the appended figures.

FIG. 1

shows a simplified perspective view of an opened drug delivery device comprising a drive mechanism.

FIG. 2

shows a cross-section according to FIG. 1 of another device.

FIG. 3

shows a cross-section according to FIG. 1 of another device.

FIG. 4

shows a cross-section according to FIG. 1 of an embodiment of the invention.

FIG. 5

shows a detail of the embodiment of FIG. 4.

[0037] Figure 1 shows a perspective view of a drug delivery device in an opened state. A housing 1 contains a drive mechanism comprising a flexible advance cable 2, which may be bent as shown in the figure. A guide means 3, which may be formed by sidewalls, for instance, is provided inside the housing 1 to guide the advance cable 2 along a prescribed way within the housing 1 and to inhibit a lateral deviation of the advance cable 2. Thus the advance cable 2 may be stored in a compact volume and operated as a driving agent.

[0038] A drive means 4 is also arranged in the housing 1 and is engaged with a coupling feature 12 on the surface of the advance cable 2. The coupling feature 12 extends along a major portion of the longitudinal extension of the advance cable 2 in order to facilitate a permanent advancement of the advance cable 2 by means of the coupling feature 12. The drive means 4 is represented in Figure 1 as a worm, and the coupling feature 12 is shown to be a screw thread, the worm and the screw thread forming a worm drive. Instead, the drive means 4 may be a pinion, a quill drive, or a similar device. Instead of a continuous screw thread, the coupling feature 12 may comprises a sequence of separate annular protrusions. The position of the drive means 4 may differ from the location shown in Figure 1. The drive means 4 may be operated by a loaded spring or by an electric motor supplied with a battery, for example. These components, which are known per se, can be applied as desired according to individual requirements and are not represented in the figures.

[0039] The housing 1 can be opened, and a cartridge 6 containing a drug may then be inserted into an empty space 19 left in the housing 1 for this purpose. In the device shown in Figure 1 the housing 1 comprises a lid 11, which may be hinged and can be opened. Figure 1 shows the cartridge 6 outside the housing 1, and the direction in which the cartridge 6 is arranged when properly inserted is indicated. An end piece 5 of the advance cable 2 is provided to push a plug 7 or bung of the cartridge 6.

[0040] When the cartridge 6 is inserted and the drive mechanism is actuated, the advance cable 2 is being advanced and the end piece 5 is maintained in contact with the plug 7 or bung, which is consequently also permanently advanced. An outlet 21 at the other end of the

cartridge 6 is arranged in or at an opening 20 of the housing 1, so that the drug is being expelled from the cartridge 6 and may be injected, by means of a needle, for instance, into a patient's body.

[0041] The end piece 5 may be an integral part of the advance cable 2, particularly if the advance cable 2 is moulded from a plastics material as one part including the end piece 5. Instead, the end piece 5 may be formed from a metal, like steel, aluminum, brass or other, and may be arranged as a separate part between the advance cable 2 and the plug 7 or bung, or may be fastened to the advance cable 2 by pressing, hammering, forging, clipping or the like.

[0042] The outer diameter of the advance cable 2 preferably corresponds to the inner diameter of the cartridge 6, at least approximately. The guide means 3 allows the drive means 4 to exert a longitudinal force on the advance cable 2, without causing a lateral deviation of the flexible advance cable 2 from the intended longitudinal path.

[0043] Figure 2 shows another device, in which the radius of curvature of the bent portion of the advance cable 2 is smaller, so that the arrangement is more compact than in the device according to Figure 1. The pitch of the screw thread may be adapted to provide the required flexibility of the advance cable 2. In Figures 1 and 2 similar elements and corresponding components are designated with the same reference numerals.

[0044] Figure 3 shows still another device, in which the position of the drive means 4 is changed, the screw thread of the coupling feature 12 has a smaller pitch, and the end piece 5 is not directly applied to and in contact with the advance cable 2. The end piece 5 is instead provided on a piston rod 13, which is shifted within a compartment that is formed by an inner sidewall 10 of the housing 1. The piston rod 13 is advanced by means of a transverse bar 8 protruding from the advance cable 2. The guide means 3 guides a portion of the advance cable 2 parallel to the movement of the piston rod 13. The advance cable 2 may be prevented from a rotation around its longitudinal axis by threads or spikes which may be formed on the surface of the advance cable 2 and may be guided in tracks 9 provided in the sidewalls 10 of the guide means 3. The bar 8, which may be formed resembling a sprig or cantilever, for example, passes through an opening formed by one of the tracks 9 and extends far enough to be able to push the piston rod 13 in the direction of the cartridge 6.

[0045] Figure 4 shows an embodiment of the invention, in which the advance cable 2 is provided with beads 14 or balls having an outer diameter that exceeds the outer diameter of the advance cable 2 and corresponds to the inner diameter of the cartridge 6. The beads 14 or balls allow the use of a thinner and therefore more flexible advance cable 2 and keep the advance cable 2 in its proper longitudinal direction with respect to the intended path of advancement. If the advance cable 2 is formed from a plastics material, the beads 14 or balls may be moulded together with the advance cable 2. Instead, the beads 14 or balls may be separate parts arranged in the compartment that is formed by the guide means 3, and the advance cable 2 may pass through openings or channels formed in the beads 14 or balls.

[0046] The beads 14 or balls may provide the coupling feature 12 which is engaged by the drive means 4. Instead, the beads 14 or balls may each comprise a recess formed in such a manner that the recesses uncover a longitudinal strip of the surface of the core of the advance cable 2. The coupling feature 12 may be provided by a toothing on said longitudinal strip, for example. The drive means 4 may comprise a worm as shown or a pinion fitting the rack that is formed by the toothing.

[0047] Figure 5 shows a detailed view of a drive means 4 which is particularly suitable in conjunction with the beaded advance cable 2 of the embodiment according to Figure 4. The drive means 4 comprises a pinion 15 engaging the coupling feature 12 on the core of the advance cable 2 within the recesses 22 of the beads 14 or balls. The axis 23 of rotation of the pinion 15 is orthogonal to the direction of longitudinal extension of the advance cable 2, which is the direction normal to the plane of the drawing. As can be seen from Figure 5, the beads 14 or balls enlarge the outer diameter 17 of the advance cable 2 to the outer diameter 18 of the beads 14 or balls.

[0048] Grooves 16 may be formed in the beads 14 or balls as a means to prevent a rotation of the advance cable 2 around its longitudinal axis and to maintain the recesses 22 of the beads 14 or balls in the appropriate position with respect to the pinion 15 or other drive means 4. The grooves 16 may be guided by corresponding threads running along the guide means 3 or along the inner sidewalls 10 of the housing 1. The position and the realisation of the drive means 4 may vary and deviate from the examples shown in the figures.

[0049] The drive mechanism and the drug delivery device provided with the drive mechanism are especially useful for infusion devices like insulin pumps, which are used to inject the drug permanently.

[0050] Further, the drive mechanism and the drug delivery device provided with the drive mechanism may be used in an injection device, for example in an injection device for injecting insulin such as long or short acting insulin. Such an injection may take place once per day for long acting insulin, or several times a day, for example before or after a meal, for other types of insulin.

Reference numerals

[0051]

1. 1 housing
2. 2 advance cable
3. 3 guide means
4. 4 drive means
5. 5 end piece
6. 6 cartridge

- 7. 7 plug
- 8. 8 bar
- 9. 9 track
- 10. 10 sidewall
- 11. 11 lid
- 12. 12 coupling feature
- 13. 13 piston rod
- 14. 14 bead
- 15. 15 pinion
- 16. 16 groove
- 17. 17 diameter of the advance cable
- 18. 18 diameter of the beads
- 19. 19 empty space
- 20. 20 opening
- 21. 21 outlet
- 22. 22 recess
- 23. 23 axis

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- [EP1372768B1](#) [0002]
- [WO0178812A1](#) [0003]
- [WO02076538A1](#) [0004]
- [WO02076535A1](#) [0005]
- [WO0172360A1](#) [0006]
- [US5261882A](#) [0007]

Non-patent literature cited in the description

- Remington's Pharmaceutical SciencesMark Publishing Company19850000 [0017]

Patentkrav

1. Drivmekanisme til en medicinafgivelsesanordning, omfattende:

- 5 - et fleksibelt fremføringskabel (2), der bærer en koblingsfunktion (12) i længderetningen
- et føringsmiddel (3), der fører fremføringskablet (2)
 - et drivmiddel (4), der griber ind i koblingsfunktionen (12) og dermed muliggør en fremføring af fremføringskablet (2) i
- 10 overensstemmelse med føringsmidlet (3), hvor drivmidlet (4) er påtænkt til permanent indgreb med koblingsfunktionen (12), hvor drivmidlet (4) er en snekke eller et tandhjul (15), og koblingsfunktionen (12) er et skruegevind, en sekvens af ringformede fremspring eller en tandstang, og
- 15 - et endestykke (5), som er påtænkt til at skubbe en prop (7) eller en spuns på en patron (6), der indeholder et lægemiddel, og som drives af fremføringskablet (2), idet fremføringskablet (2) er forsynet med perler (14) eller kugler med en udvendig diameter (18), der overstiger en ydre diameter (17) af
- 20 fremføringskablet (2) og svarer til en indvendig diameter af patronen (6), hvor endestykket (5) skubbes af et drivmiddel, der kommer ind i patronen (6) og holdes lige inde i patronen (6).

- 25 2. Drivmekanisme ifølge krav 1, hvor endestykket (5) skubbes af en del af fremføringskablet (2), der kommer ind i patronen (6).

3. Drivmekanisme ifølge krav 1 eller krav 2, hvor
- 30 fremføringskablet (2) er et plasticmateriale, og perlerne (14) eller kuglerne er udformet som integrerende dele af fremføringskablet (2).

4. Drivmekanisme ifølge krav 1 eller krav 2, hvor perlerne
- 35 (14) eller kuglerne er særskilte dele, der er arrangeret i overensstemmelse med føringsmidlet (3), og fremføringskablet (2) passerer gennem perlerne (14) eller kuglerne.

5. Drivmekanisme ifølge et hvilket som helst af kravene 1 til 4, hvor fremføringskablet (2) er et plasticmateriale, og endestykket (5) er udformet som en integrerende del af fremføringskablet (2).

5

6. Drivmekanisme ifølge et hvilket som helst af kravene 1 til 4, hvor endestykket (5) påføres fremføringskablet (2) som en særskilt del, der udgøres af et metal.

10 7. Drivmekanisme ifølge et hvilket som helst af kravene 1 til 6, hvor perlerne (14) eller kuglerne tilvejebringer den koblingsfunktion (12), der sættes i indgreb af drivmidlet (4).

15 8. Drivmekanisme ifølge et hvilket som helst af kravene 1 til 6, hvor perlerne (14) eller kuglerne hver omfatter en fordybning (22), således at fordybningerne afdækker en langsgående strimmel af overfladen af fremføringskablets (2) kerne, hvor koblingsfunktionen (12) tilvejebringes på den langsgående strimmel.

20

9. Drivmekanisme ifølge krav 8, hvor riller (16) dannes i perlerne (14) eller kuglerne for at forhindre en rotation af fremføringskablet (2) omkring dets længdeakse og for at fastholde fordybningerne (22) i den egnede position i forhold til drivmidlet (4), hvor rillerne (16) føres af tilsvarende gevind, der løber langs styremidlerne (3) eller langs de indre sidevægge af et hus (1).

25

10. Medicinafgivelsesplanlægning, der omfatter:

30 - et hus (1) og

- en drivmekanisme ifølge et hvilket som helst af kravene 1 til 9, der er anbragt inde i huset (1).

DRAWINGS



